• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    3/8/21 4:57:36 PM ET
    $IFRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IFRX alert in real time by email
    SC 13G 1 d8822325_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

     

    InflaRx N.V.
    (Name of Issuer)

     

     

     

    Common Shares, nominal value €0.12 per share
    (Title of Class of Securities)

     

     

     

    N44821101
    (CUSIP Number)

     

     

     

    February 25, 2021
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. N44821101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Suvretta Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,285,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,285,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,285,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      13.6%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IA, OO

     

     

     

    CUSIP No. N44821101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Averill Master Fund, Ltd.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,285,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,285,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,285,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      13.6%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      CO  

     

     

    CUSIP No. N44821101    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Aaron Cowen  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [x]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,285,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,285,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,285,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      13.6%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
     

    IN, HC

     

     

     

    CUSIP No. N44821101    

     

    Item 1. (a). Name of Issuer:
         
        InflaRx N.V.
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    Winzerlaer Str. 2

    07745 Jena, Germany

         
         
    Item 2. (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
       

    Suvretta Capital Management, LLC – Delaware

    Averill Master Fund, Ltd. – Cayman Islands

        Aaron Cowen – U.S.A.
         
       

    Suvretta Capital Management, LLC:

    540 Madison Avenue, 7th Floor

    New York, New York 10022

       

    United States of America

     

    Averill Master Fund, Ltd.:

    c/o Maples Corporate Services Limited

    P.O. Box 309

    Ugland House

    Grand Cayman KY1-1104

    Cayman Islands

     

    Aaron Cowen:

    c/o Suvretta Capital Management, LLC

    540 Madison Avenue, 7th Floor

    New York, New York 10022

         
      (d).   Title of Class of Securities:
         
        Common Shares, nominal value €0.12 per share (the “Common Shares”)
         
      (e). CUSIP Number:
         
        N44821101

     

     

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     

    Item 4. Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
        Suvretta Capital Management, LLC – 6,285,000
        Averill Master Fund, Ltd. – 6,285,000
        Aaron Cowen – 6,285,000
         
      (b)   Percent of class:
         
        Suvretta Capital Management, LLC – 13.6%
        Averill Master Fund, Ltd. – 13.6%
        Aaron Cowen – 13.6%

     

     

       
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (ii)   Shared power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 6,285,000
          Averill Master Fund, Ltd. – 6,285,000
          Aaron Cowen – 6,285,000
             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 6,285,000
          Averill Master Fund, Ltd. – 6,285,000
          Aaron Cowen – 6,285,000

     

     

     

     
    Item 5. Ownership of Five Percent or Less of a Class.
     


    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      All securities reported in this Schedule 13G are owned by advisory clients of Suvretta Capital Management, LLC.  None of the advisory clients, with the exception of Averill Master Fund, Ltd., individually owns more than 5% of the outstanding shares of the Common Shares.  
       

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       
    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       
    Item 10. Certification.
     
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      March 8, 2021
      (Date)
       
      Suvretta Capital Management, LLC*
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.*

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen*

     

      /s/ Aaron Cowen
      (Signature)
       
       

    *The Reporting Persons disclaim beneficial ownership over the securities reported herein except to the extent of the Reporting Persons’ pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated March 8, 2021 relating to the Common Shares, nominal value €0.12 per share of InflaRx N.V. shall be filed on behalf of the undersigned.

      March 8, 2021
      (Date)
       
      Suvretta Capital Management, LLC
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen

     

      /s/ Aaron Cowen
      (Signature)
       
       

     

     

     

    Exhibit B

     

    Aaron Cowen has beneficial ownership by virtue of his role as a control person of Suvretta Capital Management, LLC.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $IFRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IFRX

    DatePrice TargetRatingAnalyst
    4/29/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2023$8.00Neutral → Buy
    Guggenheim
    2/28/2022Buy → Neutral
    Guggenheim
    11/8/2021$14.00 → $15.00Strong Buy
    Raymond James
    10/28/2021$14.00Outperform → Strong Buy
    Raymond James
    8/6/2021$11.00 → $10.00Outperform
    Raymond James
    8/6/2021$2.80 → $2.50Underperform
    Credit Suisse
    More analyst ratings

    $IFRX
    Financials

    Live finance-specific insights

    See more
    • InflaRx to Report First Quarter 2025 Results on May 7, 2025

      JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

      4/30/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

      JENA, Germany, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and operating results for the fourth quarter and full year 2024 on March 20, 2025; no conference call is planned. InflaRx also announced that it will participate in two investor conferences. Details are as follows: Leerink Global Healthcare ConferenceMarch 9 - 12, 2025 in Miami Beach, FL InflaRx will conduct a fireside chat at the conference on March 10 at 10:40 AM ET and will participate in one-on-one-investor meetings. A link to regis

      2/25/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference

      JENA, Germany, Oct. 31, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its third quarter 2024 financial and operating results on Friday, November 8, 2024, before the market opens. No conference call is planned. In addition, InflaRx will participate in the following investor event: Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 11-13, 2024, Boston, MAFireside chat: November 11th, 11:00 am ET A link to register for the fireside chat live stream and its replay is available here. The company will also participa

      10/31/24 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Leadership Updates

    Live Leadership Updates

    See more
    • InflaRx Appoints Jan Medina as Head of Investor Relations

      JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Jan Medina, CFA, as Vice President and Head of Investor Relations of InflaRx. Mr. Medina brings over 25 years of extensive experience across the life sciences sector and capital markets, including in the areas of investor relations, communications and equity research. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: "We are delighted to welcome Jan to our team. His experience, proven track record and deep network with investors and capital mark

      2/22/24 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

      Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx's portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmaceutical industry, including leadership roles in clinical development, medical affai

      6/28/23 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on InflaRx with a new price target

      Cantor Fitzgerald initiated coverage of InflaRx with a rating of Overweight and set a new price target of $10.00

      4/29/25 8:10:45 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx upgraded by Guggenheim with a new price target

      Guggenheim upgraded InflaRx from Neutral to Buy and set a new price target of $8.00

      4/5/23 11:33:25 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx downgraded by Guggenheim

      Guggenheim downgraded InflaRx from Buy to Neutral

      2/28/22 11:38:01 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by InflaRx N.V.

      SC 13G - InflaRx N.V. (0001708688) (Subject)

      4/24/23 4:47:08 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by InflaRx N.V.

      SC 13G - InflaRx N.V. (0001708688) (Subject)

      4/17/23 4:00:10 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by InflaRx N.V. (Amendment)

      SC 13G/A - InflaRx N.V. (0001708688) (Subject)

      2/13/23 12:01:42 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

      Announces successful completion of sub-chronic and chronic toxicology studies for INF904, supporting long-term dosing in future clinical trialsMultiple near-term catalysts anticipated with the potential to substantially de-risk the Company's pipeline addressing multiple sizable marketsInterim analysis for vilobelimab Phase 3 trial in pyoderma gangrenosum (PG), to determine trial size adaptation or futility, remains on schedule with a recommendation expected to be announced at the end of May to early JuneTopline data for INF904 Phase 2a trial in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Cash, cash equivalents and marketable securities totaled

      5/7/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx to Report First Quarter 2025 Results on May 7, 2025

      JENA, Germany, April 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens. No conference call is planned. About InflaRx InflaRx (NASDAQ:IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory media

      4/30/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

      Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS)Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum (PG) to enable an expected interim analysis for trial size adaptation or futility by the end of May 2025Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904, with topline data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025Multiple data presentations at AAD 2025 highlighting the potential of vilobelimab in reducing systemic inflammationCash, cash equivalents and marketable securities of €5

      3/20/25 7:30:00 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IFRX
    SEC Filings

    See more
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      5/7/25 7:53:43 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      4/24/25 5:00:36 PM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by InflaRx N.V.

      6-K - InflaRx N.V. (0001708688) (Filer)

      4/3/25 7:31:25 AM ET
      $IFRX
      Biotechnology: Pharmaceutical Preparations
      Health Care